Caresyntax’s $100 Million Series C Funding Round

Goodwin Procter LLP advised Caresyntax on the deal.

Caresyntax announced the completion of its $100 million Series C funding round led by PFM Health Sciences LP, and included participation from Optum Ventures, Intel Capital, Lauxera Capital Partners, Vesalius Biocapital III, Arno Capital, Rezayat Investments, as well as current investors IPF Partners, the Relyens Group, and Surgical.AI. The funding will help Caresyntax accelerate expansion in key markets, further research and development of its AI analytics, build out its platforms, and expand its employee base.

Located in Berlin and the U.S., Caresyntax’s mission is to make surgery smarter and safer. The company’s enterprise-grade digital surgery platform delivers actionable insights to improve patient outcomes by using proprietary software and AI to analyze large volumes of video, audio, images, device data, clinical, and operational data in and around the OR.

The Goodwin team was led by Bill Schnoor (Picture) and Andrew Pusar.

Involved fees earner: Andrew Pusar – Goodwin Procter; William Schnoor Jr. – Goodwin Procter;

Law Firms: Goodwin Procter;

Clients: Caresyntax;

Print Friendly, PDF & Email
Federica Tiefenthaler

Author: Federica Tiefenthaler